Image Credit: Canva (representational purpose only)
Mysterious Fog in the US , Canada and UK: A dense, eerie fog with a "burning chemical-like smell" has spooked a good part of North America and parts of the United Kingdom and Canada. With social media amplifying all concerns, this phenomenon has sparked attention across all social media platforms. However, at the heart of this mysterious fog are a conjunction of natural events, social psychology, and environmental conditions that culminated in all the conspiracy theories and public health fears. Here's a closer look at the mysterious fog, its potential causes, and the societal response it has triggered.
The first reports of this "mysterious fog" came in from Florida where a resident said that they experienced respiratory symptoms, feverish warmth, and stomach cramps after contact with the fog. Similar stories started flooding social media, and within a day or two, a sinister force seemed to sweep across the United States, Canada, and parts of the UK. From Texas to Minnesota, people reported weird odors and health issues that they thought were linked to this bizarre atmospheric event.
Some witnesses were said to see "white particles" swirling through the air; theories ranged from a chemical attack or experimental weapon to drone-related chemical dispersals and references to historical military experiments, such as the infamous 1950s "Operation Sea-Spray."
Fuel to the fire were added when videos and posts, hundreds of thousands in number, began circulating on social media sites like TikTok and X (formerly Twitter) speculating on the origin of the fog. Hashtags like #ToxicFog went trending for days. Hysteria created a self-reinforcing loop in which every post spurred further scrutiny and fear.
Fog is essentially a low-lying cloud formed when the air temperature cools to its dew point, causing water vapor to condense into tiny droplets or ice crystals. Several types of fog—advection fog, radiation fog, and valley fog—can form depending on conditions such as warm, moist air moving over cooler land or when temperatures plummet rapidly under clear skies.
Such chemical-like smell as reported during the occurrence of fog events is sometimes attributed to air pollution. It acts like a sponge, where it absorbs these pollutants, which include sulfur dioxide and nitrogen oxides, among others, that emit from industries. This mixture, therefore, leads to a stench that could be mistaken as unnatural or even toxic.
Also Read: Health Concerns Rise As US, Canada, and UK Come Under The Blanket Of Thick, Dense, Toxic Fog
High moisture levels from fog can significantly exacerbate symptoms related to respiration, but especially in already predisposed asthmatics and allergy patients. The connection of these symptoms with actual fever, stomach cramps, and puffy eyes is too remote. Experts assume that the irritating effects of entrapped pollutants trapped in fog tend to affect more the eyes and throat rather than the rest of the body affected by some report.
Social media amplified a natural weather event into a health epidemic. It made the personal experience of individuals become a cause for fear and speculation, a domino effect.
According to psychologists, this is a concept of selective perception, wherein once people's attention is drawn to environmental anomalies, they begin to notice them. This mirrors earlier panics, such as the Seattle windshield pitting panic of 1954. Then, atomic bomb testing caused fear in many and started to have people looking at their windshields for small marks that they had not seen before. Likewise, postings on the strangeness of the fog probably increased public awareness and suspicion, with people looking to attach unrelated symptoms to the phenomenon.
The fog hysteria shares a commonality with other instances of mass panic, such as the "drone sightings" of recent years or the Cold War-era fears of biological warfare.
Also Read: Mysterious Fog Is Making Americans Sick
These events underscore how fear can cloud judgment, especially when amplified by social media and sensationalist headlines. While historical cases, such as "Operation Sea-Spray," offer concrete evidence of the existence of unethical experiments, the jump from a natural weather condition to theories of chemical attacks exemplifies a more modern trend of connecting unrelated dots, all wonderfully seeded in distrust and anxiety.
Despite the swirling rumors, meteorologists and scientists are in agreement that the mysterious fog is not as alarming as it seems. It is well known that fog traps and amplifies pollutants, especially in urban and industrial regions. Moreover, winter months are the most conducive for fog formation, so its recent prevalence is unsurprising.
On the other hand, environmentalists advise that the fog should wake everyone up to increased levels of pollution. The reported odors and health irritations could be just symptoms of far deeper systemic issues like industrial emissions and lack of control over air quality.
The authorities must be transparent in their communication to combat misinformation and allay public fears. Governments and environmental agencies must provide timely updates on weather phenomena, air quality, and health risks. Initiatives like real-time pollutant tracking and public education campaigns can help demystify natural occurrences while addressing valid environmental concerns.
The mysterious Canada fog is a compelling case study in how environmental events intersect with psychology and societal dynamics. While rooted in natural phenomena, the fog became a vessel for collective fears, amplified by modern technology and historical anxieties.
In this information era where communication occurs at an almost lightning pace, the fog becomes a metaphor that reminds everyone about scientific literacy, environmental responsibility, and an effective balance when considering public concern. Whether perceived as a marvel of nature or as a tale that serves to teach, it left a very powerful mark in people's minds.
After a recent Supreme Court of India order banning the use of stem cell therapy to treat autism -- a neurodevelopmental condition affecting communication, social interaction, and behavior -- the country's National Medical Commission has issued a clear warning to doctors and hospitals not to use the therapy to treat autism in routine medical practice.
The National Medical Commission, in a new advisory, asked all medical colleges, hospitals, and doctors to strictly follow the rules.
In a letter sent to the regulator, Indian Council of Medical Research Director-General Dr. Rajiv Bahl stated that the stem cell treatment can now be used in regular medical practice only for 32 diseases that are officially approved by the government. These include blood cancers and serious blood disorders such as:
Acute myeloid leukemia
Thalassemia
Multiple myeloma
Aplastic anemia
Myelofibrosis
Germ cell tumors.
The letter asked doctors not to offer stem cell therapy for any other disease outside this list.
Notably, the Ethics and Medical Registration Board (EMRB), under the National Medical Commission (NMC), had, in December 2022, constituted the Committee on Stem Cell Use in Autism Spectrum Disorder (ASD).
It had stated that none of the current international guidelines recommend stem cell therapy as a treatment for ASD and added that the therapy is not recommended as a treatment for ASD in clinical practice.
Also read: Japan Approves First-Ever Stem Cell Therapies For Parkinson’s And Heart Failure
Earlier this year, in January, a bench comprising Justice JB Pardiwala and Justice R Mahadevan noted that stem cell therapy lacks “scientific support and has not been recognized as a sound medical practice backed by empirical evidence”.
The Bench ruled that “every use of stem cells in patients outside an approved clinical trial is unethical and shall be considered as malpractice.”
The apex Court, however, added that the advanced therapy, which holds promise in several medical fields, can still be approved for monitored clinical research trials. It added that the patients have the liberty to participate in approved and regulated clinical trials.
Stem cell therapy, also called regenerative medicine, is a medical treatment that uses stem cells to repair or replace damaged tissues.
While the therapy is useful and effective for blood cancers and autoimmune diseases, for the treatment of autism, there is no proof or scientific evidence of its utility.
As stem cell therapy is vastly unregulated in India, many private labs have been minting money over the promise of treatment for autism.
“Most stem cell therapies are unregulated in India and are promoted based on no evidence, and fake advertisements. While these disorders have no cure, many people are falsely lured by these companies,” Dr. Manjari Tripathi, Head of Department, Neurology, AIIMS Delhi, had told IANS, after the SC verdict.
Also read: New Stem Cell Transplant Breakthrough Could Replace Chemo In Cancer Treatment
The NMC warned that any doctor or institution offering stem cell therapy for autism will face regulatory and legal action.
The top medical regulator, however, stated that stem cell therapy is permissible only for research purposes.
Such studies must follow strict rules set by the government and must be approved by ethics committees and national regulatory bodies.
Researchers must also ensure that patients give written consent, that treatment is provided free during the trial, and compensation is offered if injury or death occurs during research.
Credits: Canva and Wikimedia Commons
Florida on Tuesday approved nearly $31 million in short-term funding for H.I.V. medication for residents This is a reverse course after the state health officials restricted the access to a program that helps only those who could afford costly medications.
The Florida Department of Health had imposed tougher eligibility rules on March 1 that left 12,000 residents with H.I.V. without the access to medication covered by the state's AIDS Drug Assistance Program. This deprived them of life saving drugs, noted a nonprofit advocacy group - AIDS Healthcare Foundation.
The foundation also sued the department over these changes with protestors rallying in opposition at the State Capitol in Tallahassee. The department cited a projected $120 million state budget that restricted eligibility for the program.
Read: HIV vs. AIDS: What You Should Know About These Commonly Confused Terms
Yet, the Florida House of Representatives and State Senate, both led by Republicans, unanimously approved legislation that provides $30.9 million to fund the program through June 30 and restore the eligibility rules. Gov. Ron DeSantis, a Republican, signed the bill into law on Tuesday.
“Lawmakers on both sides understood the urgency of the crisis,” State Senator Carlos Guillermo Smith, a Democrat from Orlando who spoke out in support of the bill on the floor, said in an interview on Wednesday. “It is a matter of life and death. People had already lost access to their medications.”
As per an analysis by KFF - a health research group, Florida was one of the nearly 20 states, led both by Republicans and Democrats that imposed restrictions on AIDS Drug Assistance Programs.
The programs cover the cost of H.I.V. medications, which can run into thousands of dollars each month. They provide drugs free to some individuals and help others by paying their insurance premiums. Overall, they support about a quarter of the 1.2 million people living with H.I.V. in the United States.
However, these programs are under growing pressure. The cost of H.I.V. medications continues to rise, and the expiration of health care subsidies has led to a sharp increase in insurance premiums. Despite this, federal funding for these programs has remained largely unchanged for more than a decade.
In Florida, the Department of Health had reduced eligibility for the state’s AIDS Drug Assistance Program to 130 percent of the federal poverty level, which is about $20,748 a year for an individual, down from 400 percent or $63,840. A new law has now reversed this change, restoring eligibility back to the 400 percent threshold.
“For 10 weeks, 12,000 Floridians living with H.I.V. did not know if they could fill their next prescription,” Esteban Wood, the director of advocacy and legislative affairs at the AIDS Healthcare Foundation, said in a statement on Tuesday. “Today, they can.”
Credit: Wikimedia Commons
The US Food and Drug Administration (FDA) has approved a drug therapy to address neurologic symptoms of a rare genetic disorder — Hunter syndrome.
The X-chromosome-linked disease, occurring predominantly in males, has an estimated 2,000 affected individuals worldwide.
The drug Avlayah, developed by pharma company Denali Therapeutics, targets certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
It is the first therapy to address the neurologic complications of Hunter Syndrome, such as
“Today is a milestone day for children and their families battling Hunter syndrome,” said FDA Commissioner Marty Makary, in a statement.
“Avlayah is the first product approved to address neurologic complications of Hunter Syndrome, a very rare and often severe X-linked disorder in children, affecting about 500 people in the US, almost exclusively males,” added Acting CDER Director Dr. Tracy Beth Hoeg.
The FDA noted that Avlayah, the once-weekly drug given via IV infusion, must begin in presymptomatic or symptomatic pediatric patients weighing at least 5 kg before advanced neurologic impairment.
Hunter syndrome is a rare inherited lysosomal disorder in which sugar molecules called glycosaminoglycans build up within the cells’ lysosomes.
The condition affects physical and mental development and causes abnormalities in the skeleton, heart, respiratory system, brain, and other organs.
Hunter syndrome is a rare congenital metabolic disease. It was first reported in 1917 by a Canadian physician, Charles Hunter, in two brothers in a family.
The brothers presented typical signs, such as
The younger brother had symptoms of Central Nervous System (CNS), including seizures and cognitive decline, while the older brother did not have CNS involvement.
The estimated incidence is 1 in 162,000 live male births.
The FDA approval came after Avlayah showed promise in reducing cerebrospinal fluid heparan sulfate — one of the glycosaminoglycans that accumulates in the body in this disorder and is linked to the organ damage that occurs in early childhood.
The phase 1/2 multi-cohort, single-arm, open-label trial enrolled 47 pediatric patients with Hunter syndrome aged 3 months to 13 years.
Of these, 44 patients with measurements at had a 91 percent average decrease from baseline in CSF.
Denali is now conducting a randomized clinical trial that is more than 95 percent enrolled to evaluate the clinical benefit of this product.
"In the meantime, families with young children with Hunter Syndrome will have access to a product that may favorably alter the course of the disease at the crucial time in life when there is the greatest potential for benefit," Hoeg said.
Avlayah’s labeling includes a boxed warning for allergic reactions, including anaphylaxis, associated with the drug.
The FDA recommended that patients start therapy in a health care setting with appropriate medical monitoring and support measures.
The common side effects of Avlayah include
The FDA also suggested that healthcare workers monitor
© 2024 Bennett, Coleman & Company Limited